{
    "clinical_study": {
        "@rank": "124347", 
        "arm_group": {
            "arm_group_label": "Advanced solid tumours"
        }, 
        "biospec_descr": {
            "textblock": "Blood samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical\n      Company, Ltd, and is currently undergoing clinical investigation at the National University\n      Health System (NUHS), Singapore. The proposed correlative pharmacodynamic and\n      pharmacogenetic biomarker study is initiated and funded by the investigators, and will be\n      conducted in conjunction with the extension phase I protocol of OPB-51602 in patients with\n      advanced solid tumours (Study code 266-09-801-01/ DSRB protocol B/09/514). All biomarker and\n      pharmacogenetic samples will be collected, stored and analysed at the local laboratory of\n      the study site (Cancer Science Institute, National University Health System, Singapore, Dr\n      Boon-Cher Goh)."
        }, 
        "brief_title": "A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Advanced Solid Tumor\n\n        Exclusion Criteria:\n\n        Non advanced solid tumor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study will enroll patients from the extension cohort an ongoing phase I study of\n        OPB51602, to study the tumour response in selected tumour types, as a proof of concept."
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867073", 
            "org_study_id": "PG01/04/11"
        }, 
        "intervention": {
            "arm_group_label": "Advanced solid tumours", 
            "description": "-", 
            "intervention_name": "Biomarker", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore"
                }, 
                "name": "National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_groups": "1", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Singapore: Domain Specific Review Boards", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Analysis", 
            "measure": "Inhibition of STAT3 phosphorylation in peripheral mononuclear blood cells (PBMCs)pharmacodynamic effect of OPB-51602 in surrogate tissue.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "reference": [
            {
                "PMID": "14964307", 
                "citation": "Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004 Feb;4(2):97-105. Review."
            }, 
            {
                "PMID": "11948098", 
                "citation": "Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002 Apr;8(4):945-54. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867073"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Analysis", 
            "measure": "To identify single nucleotide polymorphisms (SNPs) that correlate with OPB-51602 pharmacokinetics and pharmacodynamics", 
            "safety_issue": "No", 
            "time_frame": "1 Year"
        }, 
        "source": "National University Hospital, Singapore", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National University Hospital, Singapore", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}